Intellia Therapeutics (NTLA) Retained Earnings (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Retained Earnings of -$2.7 billion for Q1 2026, down 254246.17% year-over-year from N/an in Q1 2025, and down 3.72% quarter-over-quarter from -$2.6 billion in Q4 2025.
Intellia Therapeutics (NTLA) Retained Earnings (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Retained Earnings for 12 consecutive years, with -$2.7 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 254246.17% year-over-year to -$2.7 billion; the TTM figure through Mar 2026 stood at -$2.7 billion (down 254246.17% YoY), while the FY2025 annual figure was -$2.6 billion, down 18.95% from the prior year.
- Retained Earnings retreated to -$2.7 billion in Q1 2026 per NTLA's latest filing, from -$2.6 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $1.1 million in Q1 2025 and bottomed at -$2.7 billion in Q1 2026.
- Historically, Retained Earnings has averaged -$1.1 billion across 5 years, with a median of -$1.1 billion in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings slumped 7311830.77% — and 2025, when it surged 211.62%.
- Intellia Therapeutics' Retained Earnings stood at -$1.2 billion in 2022, then tumbled by 40.88% to -$1.7 billion in 2023, then tumbled by 31.3% to -$2.2 billion in 2024, then retreated by 18.95% to -$2.6 billion in 2025, then declined by 3.72% to -$2.7 billion in 2026.
- Business Quant data shows NTLA's Retained Earnings at -$2.7 billion in Q1 2026, -$2.6 billion in Q4 2025, and -$2.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | -2.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.79 Bn |
| Mar 31, 2026 | -2.69 Bn |
| Dec 31, 2025 | -2.59 Bn |
| Sep 30, 2025 | -2.49 Bn |
| Jun 30, 2025 | 653,000.00 |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | -2.18 Bn |
| Sep 30, 2024 | -2.05 Bn |
| Jun 30, 2024 | -1.16 Mn |
| Mar 31, 2024 | -947,000.00 |
| Dec 31, 2023 | -1.66 Bn |
| Sep 30, 2023 | -1.53 Bn |
| Jun 30, 2023 | -3.87 Mn |
| Mar 31, 2023 | -2.68 Mn |
| Dec 31, 2022 | -1.18 Bn |
| Sep 30, 2022 | -1.06 Bn |
| Jun 30, 2022 | -950.55 Mn |
| Mar 31, 2022 | -8.06 Mn |
| Dec 31, 2021 | -2.63 Mn |
| Sep 30, 2021 | -174,000.00 |